Home › Companies › Theravance Biopharma, Inc. › 2024-2025
Compiled from SEC Form N-PX filings and Theravance Biopharma, Inc.’s Form 8-K, filed May 20, 2025 (Item 5.07 on EDGAR). Page generated October 25, 2026.
Meeting of May 19, 2025: 6 items on Theravance Biopharma, Inc.’s Form 8-K, filed May 20, 2025: 4 elected · 2 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore Theravance Biopharma, Inc. in the interactive database Compare manager voting policies
These tallies are Theravance Biopharma, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 20, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Rick E Winningham | 28,586,164 | 1,965,694 | 9,513,702 | -- | 5,680,519 | 94% | Elected | — |
| Elect Director: Jeremy T. Grant | 39,915,281 | 145,969 | 4,310 | -- | 5,680,519 | 99.6% | Elected | — |
| Elect Director: Susannah Gray | 39,943,074 | 110,833 | 11,653 | -- | 5,680,519 | 99.7% | Elected | — |
| Elect Director: Donal O'Connor | 39,871,814 | 180,335 | 13,411 | -- | 5,680,519 | 99.5% | Elected | — |
| Number of Shares Voted | 45,165,816 | 578,070 | 2,193 | -- | -- | 99% | Not verified | — |
| Number of Shares Voted | 30,154,992 | 374,257 | 9,536,311 | -- | 5,680,519 | 99% | Not verified | — |
Source: Theravance Biopharma, Inc., Form 8-K, filed with the SEC on May 20, 2025 — read the filing on EDGAR.
Each item below shows how the 134 asset managers that disclosed a Theravance Biopharma, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Theravance Biopharma, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 2 wordings of this item as funds reported it.
99.5% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Donal O'Connor
Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Donal O'Connor”): 39,871,814 for, 180,335 against, per its Form 8-K filed May 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal One – Based on the following results of voting, the nominees listed below were elected Class II directors to serve as members of the Board until the Company's Annual General Meeting held in 2026 and until their successors are duly elected and qualified:”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 41 asset managers below reported 5,693,981 for, 153 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,032,752 | 0 | 0 | 0 | For |
| BlackRock | 784,409 | 0 | 0 | 0 | For |
| Fidelity | 784,126 | 0 | 0 | 0 | For |
| Dimensional | 389,482 | 0 | 0 | 0 | For |
| TIAA | 373,658 | 0 | 0 | 0 | For |
| Charles Schwab | 294,870 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 208,783 | 0 | 0 | 0 | For |
| Equitable | 139,894 | 0 | 0 | 0 | For |
| American Century | 84,971 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 62,311 | 0 | 0 | 0 | For |
| Lincoln Financial | 51,525 | 0 | 0 | 0 | For |
| SEI | 42,867 | 0 | 0 | 0 | For |
| Global X | 40,331 | 0 | 0 | 0 | For |
| Northern Trust | 37,315 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 37,207 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 35,426 | 0 | 0 | 0 | For |
| Goldman Sachs | 34,162 | 0 | 0 | 0 | For |
| Nationwide | 30,255 | 0 | 0 | 0 | For |
| T. Rowe Price | 27,164 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 26,356 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 18,554 | 0 | 0 | 0 | For |
| Pacific Life | 18,323 | 0 | 0 | 0 | For |
| GuideStone | 16,356 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 16,283 | 0 | 0 | 0 | For |
| John Hancock | 14,681 | 0 | 0 | 0 | For |
Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Jeremy T. Grant
Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Jeremy T. Grant”): 39,915,281 for, 145,969 against, per its Form 8-K filed May 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal One – Based on the following results of voting, the nominees listed below were elected Class II directors to serve as members of the Board until the Company's Annual General Meeting held in 2026 and until their successors are duly elected and qualified:”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 41 asset managers below reported 5,693,981 for, 153 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,032,752 | 0 | 0 | 0 | For |
| BlackRock | 784,409 | 0 | 0 | 0 | For |
| Fidelity | 784,126 | 0 | 0 | 0 | For |
| Dimensional | 389,482 | 0 | 0 | 0 | For |
| TIAA | 373,658 | 0 | 0 | 0 | For |
| Charles Schwab | 294,870 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 208,783 | 0 | 0 | 0 | For |
| Equitable | 139,894 | 0 | 0 | 0 | For |
| American Century | 84,971 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 62,311 | 0 | 0 | 0 | For |
| Lincoln Financial | 51,525 | 0 | 0 | 0 | For |
| SEI | 42,867 | 0 | 0 | 0 | For |
| Global X | 40,331 | 0 | 0 | 0 | For |
| Northern Trust | 37,315 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 37,207 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 35,426 | 0 | 0 | 0 | For |
| Goldman Sachs | 34,162 | 0 | 0 | 0 | For |
| Nationwide | 30,255 | 0 | 0 | 0 | For |
| T. Rowe Price | 27,164 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 26,356 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 18,554 | 0 | 0 | 0 | For |
| Pacific Life | 18,323 | 0 | 0 | 0 | For |
| GuideStone | 16,356 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 16,283 | 0 | 0 | 0 | For |
| John Hancock | 14,681 | 0 | 0 | 0 | For |
Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.
Combines 2 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Rick E Winningham
Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Rick E Winningham”): 28,586,164 for, 1,965,694 against, per its Form 8-K filed May 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal One – Based on the following results of voting, the nominees listed below were elected Class II directors to serve as members of the Board until the Company's Annual General Meeting held in 2026 and until their successors are duly elected and qualified:”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 41 asset managers below reported 5,694,134 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,032,752 | 0 | 0 | 0 | For |
| BlackRock | 784,409 | 0 | 0 | 0 | For |
| Fidelity | 784,126 | 0 | 0 | 0 | For |
| Dimensional | 389,482 | 0 | 0 | 0 | For |
| TIAA | 373,658 | 0 | 0 | 0 | For |
| Charles Schwab | 294,870 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 208,783 | 0 | 0 | 0 | For |
| Equitable | 139,894 | 0 | 0 | 0 | For |
| American Century | 84,971 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 62,311 | 0 | 0 | 0 | For |
| Lincoln Financial | 51,525 | 0 | 0 | 0 | For |
| SEI | 42,867 | 0 | 0 | 0 | For |
| Global X | 40,331 | 0 | 0 | 0 | For |
| Northern Trust | 37,315 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 37,207 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 35,426 | 0 | 0 | 0 | For |
| Goldman Sachs | 34,162 | 0 | 0 | 0 | For |
| Nationwide | 30,255 | 0 | 0 | 0 | For |
| T. Rowe Price | 27,164 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 26,356 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 18,554 | 0 | 0 | 0 | For |
| Pacific Life | 18,323 | 0 | 0 | 0 | For |
| GuideStone | 16,356 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 16,283 | 0 | 0 | 0 | For |
| John Hancock | 14,681 | 0 | 0 | 0 | For |
Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Susannah Gray
Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Susannah Gray”): 39,943,074 for, 110,833 against, per its Form 8-K filed May 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal One – Based on the following results of voting, the nominees listed below were elected Class II directors to serve as members of the Board until the Company's Annual General Meeting held in 2026 and until their successors are duly elected and qualified:”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 41 asset managers below reported 5,690,536 for, 3,598 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,032,752 | 0 | 0 | 0 | For |
| BlackRock | 784,409 | 0 | 0 | 0 | For |
| Fidelity | 784,126 | 0 | 0 | 0 | For |
| Dimensional | 389,482 | 0 | 0 | 0 | For |
| TIAA | 373,658 | 0 | 0 | 0 | For |
| Charles Schwab | 294,870 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 208,783 | 0 | 0 | 0 | For |
| Equitable | 139,894 | 0 | 0 | 0 | For |
| American Century | 84,971 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 62,311 | 0 | 0 | 0 | For |
| Lincoln Financial | 51,525 | 0 | 0 | 0 | For |
| SEI | 42,867 | 0 | 0 | 0 | For |
| Global X | 40,331 | 0 | 0 | 0 | For |
| Northern Trust | 37,315 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 37,207 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 35,426 | 0 | 0 | 0 | For |
| Goldman Sachs | 34,162 | 0 | 0 | 0 | For |
| Nationwide | 30,255 | 0 | 0 | 0 | For |
| T. Rowe Price | 27,164 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 26,356 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 18,554 | 0 | 0 | 0 | For |
| Pacific Life | 18,323 | 0 | 0 | 0 | For |
| GuideStone | 16,356 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 16,283 | 0 | 0 | 0 | For |
| John Hancock | 14,681 | 0 | 0 | 0 | For |
Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99% Fund and manager reports combined; may count the same shares twice · no official result
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,032,752 | 0 | 0 | 0 | For |
| BlackRock | 784,409 | 0 | 0 | 0 | For |
| Fidelity | 784,126 | 0 | 0 | 0 | For |
| Dimensional | 389,482 | 0 | 0 | 0 | For |
| TIAA | 373,658 | 0 | 0 | 0 | For |
| Charles Schwab | 294,870 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 208,783 | 0 | 0 | 0 | For |
| Equitable | 139,894 | 0 | 0 | 0 | For |
| American Century | 0 | 84,971 | 0 | 0 | Against |
| Columbia Threadneedle | 62,311 | 0 | 0 | 0 | For |
| Lincoln Financial | 51,525 | 0 | 0 | 0 | For |
| SEI | 42,867 | 0 | 0 | 0 | For |
| Global X | 40,331 | 0 | 0 | 0 | For |
| Northern Trust | 37,315 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 37,207 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 35,426 | 0 | 0 | 0 | For |
| Goldman Sachs | 34,162 | 0 | 0 | 0 | For |
| Nationwide | 30,255 | 0 | 0 | 0 | For |
| T. Rowe Price | 27,164 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 26,356 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 18,554 | 0 | 0 | 0 | For |
| Pacific Life | 18,323 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 16,283 | 0 | 0 | 0 | For |
| John Hancock | 14,681 | 0 | 0 | 0 | For |
| Brighthouse | 14,122 | 0 | 0 | 0 | For |
Fund voting reports, all 40 managers: 5,592,654 for, 85,124 against. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Madison Avenue Partners, LP | 0 | 0 | 9,511,150 | 0 | Abstain |
| Weiss Asset Management LP | 7,457,060 | 0 | 0 | 0 | For |
| Newtyn Management, LLC | 6,309,408 | 0 | 0 | 0 | For |
| Irenic Capital Management LP | 2,513,541 | 0 | 0 | 0 | For |
| Park West Asset Management LLC | 1,804,244 | 0 | 0 | 0 | For |
| BlackRock | 1,213,093 | 0 | 0 | 0 | For |
| Camber Capital Management LP | 1,000,000 | 0 | 0 | 0 | For |
| State Street | 961,404 | 1,966 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 863,080 | 0 | 0 | 0 | For |
| DE Shaw | 860,484 | 0 | 0 | 0 | For |
| Nuveen | 374,952 | 0 | 0 | 0 | For |
| Charles Schwab | 295,867 | 0 | 0 | 0 | For |
| Northern Trust | 211,343 | 2,910 | 0 | 0 | For |
| Citadel | 139,476 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 0 | 131,407 | 0 | 0 | Against |
| MELLON INVESTMENTS Corp | 119,139 | 0 | 0 | 0 | For |
| Wellington | 112,795 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 106,088 | 0 | 0 | 0 | For |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 100,933 | 0 | 0 | 0 | For |
| Dimensional | 86,415 | 0 | 0 | 0 | For |
| American Century | 0 | 84,971 | 0 | 0 | Against |
| T. Rowe Price | 78,053 | 0 | 0 | 0 | For |
| AllianceBernstein | 73,380 | 0 | 0 | 0 | For |
| NJ State Employees Deferred Compensation Plan | 0 | 58,142 | 0 | 0 | Against |
| Russell Investments | 54,230 | 0 | 0 | 0 | For |
Institutional-manager reports, all 107 managers: 25,218,438 for, 294,933 against, 9,521,331 abstained. Showing the 25 largest; see all in the interactive database.
99.9% of fund votes cast · no official result
Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THERAVANCE BIOPHARMA, INC.'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.
The 40 asset managers below reported 5,674,027 for, 3,751 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,032,752 | 0 | 0 | 0 | For |
| BlackRock | 784,409 | 0 | 0 | 0 | For |
| Fidelity | 784,126 | 0 | 0 | 0 | For |
| Dimensional | 389,482 | 0 | 0 | 0 | For |
| TIAA | 373,658 | 0 | 0 | 0 | For |
| Charles Schwab | 294,870 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 208,783 | 0 | 0 | 0 | For |
| Equitable | 139,894 | 0 | 0 | 0 | For |
| American Century | 84,971 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 62,311 | 0 | 0 | 0 | For |
| Lincoln Financial | 51,525 | 0 | 0 | 0 | For |
| SEI | 42,867 | 0 | 0 | 0 | For |
| Global X | 40,331 | 0 | 0 | 0 | For |
| Northern Trust | 37,315 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 37,207 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 35,426 | 0 | 0 | 0 | For |
| Goldman Sachs | 34,162 | 0 | 0 | 0 | For |
| Nationwide | 30,255 | 0 | 0 | 0 | For |
| T. Rowe Price | 27,164 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 26,356 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 18,554 | 0 | 0 | 0 | For |
| Pacific Life | 18,323 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 16,283 | 0 | 0 | 0 | For |
| John Hancock | 14,681 | 0 | 0 | 0 | For |
| Brighthouse | 14,122 | 0 | 0 | 0 | For |
Showing the 25 largest of 40 asset managers. See all 40 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 50,001,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.07% |
| 2 | BlackRock | 1.57% |
| 3 | Fidelity | 1.57% |
| 4 | Dimensional | 0.78% |
| 5 | TIAA | 0.75% |
| 6 | Charles Schwab | 0.59% |
| 7 | Delaware/Macquarie | 0.42% |
| 8 | Equitable | 0.28% |
| 9 | American Century | 0.17% |
| 10 | Columbia Threadneedle | 0.12% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Madison Avenue Partners, LP | 19.02% |
| 2 | Weiss Asset Management LP | 14.91% |
| 3 | Newtyn Management, LLC | 12.62% |
| 4 | Irenic Capital Management LP | 5.03% |
| 5 | Park West Asset Management LLC | 3.61% |
| 6 | BlackRock | 2.43% |
| 7 | Camber Capital Management LP | 2.00% |
| 8 | State Street | 1.93% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.73% |
| 10 | DE Shaw | 1.72% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Madison Avenue Partners, LP | 19.02% | DEF14A |
| Weiss Asset Management LP | 14.91% | 13D |
| Newtyn Management, LLC | 8.60% | 13G |
| BlackRock | 6.90% | 13F |
| Irenic Capital Management LP | 5.52% | DEF14A |
| Vanguard Group | 4.16% | 13F |
| Rick E Winningham | 3.52% | DEF14A |
| State Street | 2.13% | 13F |
| D.E. Shaw | 1.84% | 13F |
| Geode Capital | 1.78% | 13F |
Percentages above are of 50,001,000 shares outstanding, as reported by Theravance Biopharma, Inc. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Theravance Biopharma, Inc.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on October 25, 2026; a live search always shows the current data.
At Theravance Biopharma, Inc.'s shareholder meeting held May 19, 2025, in the 2024-2025 proxy season, 134 asset managers reported how they voted in their SEC Form N-PX filings, covering 931 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Theravance Biopharma, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To vote on a non-binding advisory resolution regarding the compensation of our named executive… — the reporting funds and managers cast 99% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.
Theravance Biopharma, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Download data (CSV): ballot items · votes by manager · column guide.